Skip to main content

Table 1 Patient characteristics in each of the phase III clinical studies, OSKIRA-1, -2 and -3.

From: Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis

Study

OSKIRA 1

OSKIRA 2

OSKIRA 3

p

N

206

197

71

 

Gender, n (%)

Females

173 (84%)

169 (86)

55 (78)

> 0.1

Age

53.0 (12.0)

54.4 (12.5)

54.1 (12.7)

> 0.1

BMI

28.0 (6.1)

28.0 (6.4)

29.7 (6.7)

> 0.1

Ethnicity, n (%)

African decent

4 (2)

13 (6.6)

6 (8.4)

< 0.0001

ASIAN

1 (0.5)

20 (10.2)

0

Caucasian

108 (52.4)

150 (76.1)

37 (52.1)

Hispanic or Latino

93 (45.1)

12 (6.1)

28 (39.4)

Other

0

2 (1.0%)

0

Disease duration, years (SD)

9.1 (7.9)

7.5 (8.6)

10.2 (7.8)

< 0.0001

Disease activity score, mean (SD)

5.9 (0.8)

5.6 (0.9)

5.6 (0.4)

> 0.1

Presence of erosions at baseline

Yes

100 (49.8)

93 (47.2)

37 (52.1)

> 0.1

Previous conventional DMARDs

Yes

76 (36.9)

64 (32.5)

22 (31.0)

> 0.1

Previous anti-TNFa treatment

Yes

10 (4.9%)

36 (18.3%)

71 (100%)

< 0.0001

Previous other biologics

Yes

0 (0%)

0 (0%)

0 (0%)

> 0.1

Escape at week 12

Yes

66 (32.0)

90 (45.7)

25 (35.2)

0.016

  1. Data is presented as mean (SD) or frequency (%) as appropriated. Significant difference between studies was estimated by either χ2 or Kruskal-Wallis test (alpha = 0.05)